Speaker: Dean Fennell

Liz Darlison and Dean Fennell

Mesothelioma UK

Professor Dean Fennell, “Oncology: Advancements and Challenges in Treating Mesothelioma“

ADAO

Assessing the link between the gut microbiome and response rates in mesothelioma

Overview of therapeutic targets of interest in the treatment of mesothelioma

ATOMIC: treating mesothelioma with an arginine-degrading enzyme and combination chemotherapy

Role of immunotherapy in the management of mesothelioma

MITOPE: RSO-021, a novel PRX3 inhibitor, in mesothelioma or other pleural cancers

Mesothelioma: the key unanswered question

The need for RCTs in immunotherapy for mesothelioma

MiST5: niraparib and dostarlimab in relapsed malignant mesothelioma

Vinorelbine in Mesothelioma: the upcoming VIM trial

Targeting the tumor vasculature in mesothelioma

Personalized medicine in mesothelioma

Advances in mesothelioma treatment

Abemaciclib in patients with p16ink4a negative, relapsed mesothelioma

Personalized therapy in thoracic malignancies

MiST: personalized approaches to mesothelioma treatment

Discussion of the results from the BEAT-meso trial in pleural mesothelioma

Cutting-edge UK trials for mesothelioma: double immuno, arginine depletion and molecular profiling

Therapeutic targets for mesothelioma and sarcomatoid carcinoma